The Making of I‑BET762, a BET Bromodomain Inhibitor Now in Clinical Development

Bromodomain and extra-terminal (BET) proteins belong to a class of proteins collectively called epigenetic “readers”. BET bromodomains have emerged as promising drug targets for treatment of cancers, inflammatory diseases, and other medical conditions. GlaxoSmithKline scientists have successfully op...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2013-10, Vol.56 (19), p.7498-7500
Hauptverfasser:	Zhao, Yujun, Yang, Chao-Yie, Wang, Shaomeng
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Benzodiazepines - pharmacology Humans Nuclear Proteins - antagonists & inhibitors Transcription Factors - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!